ZA984268B - Method and composition for administering taxanes orally to human patients - Google Patents

Method and composition for administering taxanes orally to human patients

Info

Publication number
ZA984268B
ZA984268B ZA984268A ZA984268A ZA984268B ZA 984268 B ZA984268 B ZA 984268B ZA 984268 A ZA984268 A ZA 984268A ZA 984268 A ZA984268 A ZA 984268A ZA 984268 B ZA984268 B ZA 984268B
Authority
ZA
South Africa
Prior art keywords
composition
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
ZA984268A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of ZA984268B publication Critical patent/ZA984268B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA984268A 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients ZA984268B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (1)

Publication Number Publication Date
ZA984268B true ZA984268B (en) 1999-06-23

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984268A ZA984268B (en) 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (xx)
JP (1) JP2002500667A (xx)
KR (1) KR100615783B1 (xx)
CN (2) CN1261275A (xx)
AR (1) AR012731A1 (xx)
AT (1) ATE308365T1 (xx)
AU (1) AU7130098A (xx)
BR (1) BR9809694A (xx)
CA (1) CA2290446C (xx)
CZ (1) CZ9904244A3 (xx)
DE (1) DE69832173T2 (xx)
DK (1) DK0994706T3 (xx)
ES (1) ES2247690T3 (xx)
HK (1) HK1026637A1 (xx)
HU (1) HUP0003546A3 (xx)
IL (2) IL132992A0 (xx)
NO (1) NO995812L (xx)
PL (1) PL337064A1 (xx)
RU (1) RU2205005C2 (xx)
SK (1) SK157599A3 (xx)
UA (1) UA74767C2 (xx)
WO (1) WO1998053811A1 (xx)
ZA (1) ZA984268B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
ATE219363T1 (de) * 1997-06-20 2002-07-15 Baker Norton Pharma Lösliche prodrugs von paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU4955200A (en) 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
JP2004520398A (ja) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2763893A1 (en) * 2009-06-02 2010-12-09 Nikan Pharmaceuticals, Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
JP2024512472A (ja) * 2021-03-17 2024-03-19 ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ タキサンに対する過敏性反応を治療するためのc5ar1阻害薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ ウエルカム ファウンデーション リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
AU652996B2 (en) * 1991-01-11 1994-09-15 Laboratoires Glaxo S.A. Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CZ293076B6 (cs) * 1994-07-26 2004-02-18 Indena S. P. A. Polosyntetické taxany, způsob jejich výroby, farmaceutické prostředky s jejich obsahem a meziprodukty pro jejich výrobu
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR100661879B1 (ko) * 1998-04-01 2006-12-27 스키에파마 캐나다 인코포레이티드 항암 조성물

Also Published As

Publication number Publication date
CA2290446A1 (en) 1998-12-03
DE69832173T2 (de) 2006-08-03
HK1026637A1 (en) 2000-12-22
WO1998053811A1 (en) 1998-12-03
CZ9904244A3 (cs) 2001-10-17
AR012731A1 (es) 2000-11-08
RU2205005C2 (ru) 2003-05-27
EP0994706B1 (en) 2005-11-02
KR100615783B1 (ko) 2006-08-25
DE69832173D1 (de) 2005-12-08
EP0994706A1 (en) 2000-04-26
CN1550231A (zh) 2004-12-01
KR20010013025A (ko) 2001-02-26
IL132992A (en) 2006-08-20
NO995812D0 (no) 1999-11-26
CN1261275A (zh) 2000-07-26
BR9809694A (pt) 2000-10-03
IL132992A0 (en) 2001-03-19
DK0994706T3 (da) 2006-03-06
UA74767C2 (en) 2006-02-15
ES2247690T3 (es) 2006-03-01
SK157599A3 (en) 2002-10-08
PL337064A1 (en) 2000-07-31
AU7130098A (en) 1998-12-30
HUP0003546A3 (en) 2002-12-28
NO995812L (no) 2000-01-25
ATE308365T1 (de) 2005-11-15
CA2290446C (en) 2008-01-29
HUP0003546A2 (hu) 2002-11-28
EP0994706A4 (en) 2001-05-16
JP2002500667A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
PL341592A1 (en) Method of administering human aspb28 insulin
HUP0103357A3 (en) Halichondrin analogs and methods of their use and preparation
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
HK1151462A1 (zh) 用於將物質給藥的植入物以及製備植入物的方法
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
PL344246A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
ZA984268B (en) Method and composition for administering taxanes orally to human patients
EP1129217A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
IL122405A (en) Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1181022A4 (en) MEDICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP1210075A4 (en) COMPILATIONS AND METHODS FOR CHANGING THE FAT IN THE SKIN
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
EP1009433A4 (en) THERAPEUTIC COMPOSITION AND TREATMENT METHOD
AU784159C (en) Method and compositions for administering taxanes orally to human patients
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
HU9801869D0 (en) Pharmaceutical composition for enhancing level of l-carnitin in human patients
GB9608927D0 (en) Method of treatment and pharmaceutical composition